Will Nilotinib be reduced in price or included in medical insurance in 2025?

The original drug of nilotinib has been officially launched in China, with the trade name Tasigna (Tasigna). The drug has been included in the national Class B medical insurance, but reimbursement eligibility is limited to patients who meet the indications. Nilotinib is mainly used to treat patients with chronic myelogenous leukemia (CML), especially for patients who are resistant or intolerant to imatinib. Medical insurance coverage has greatly reduced the financial burden on patients, but indications and medication guidelines still need to be strictly followed.

In the domestic market, the common specifications of nilotinib are150mg*120 tablets, and each box sells for about 10,000 yuan. Due to the existence of medical insurance reimbursement, the actual amount paid by the patient will vary depending on the region and specific medical insurance policies. For eligible patients, the cost after medical insurance reimbursement is significantly reduced, allowing more patients to receive standardized targeted therapy and improving treatment compliance and efficacy.

In addition, nilotinib is also sold in overseas markets. The price of the original version in India is relatively low, with each box selling for about 2,000 yuan. The price will fluctuate due to exchange rate changes. There are also many generic versions on the market overseas. For example, the generic version of nilotinib produced by Lucius Pharmaceutical Factory in Laos is 150mg*28 tablets. Each box sells for about more than 1,000 yuan. Generic drugs are more affordable, but patients need to ensure formal purchasing channels to ensure drug quality and safety when choosing.

To sum up, the original drug nilotinib has been officially launched in China and is included in medical insurance, which greatly facilitates the treatment of patients with chronic myelogenous leukemia. However, because drug prices are still high, some patients may choose overseas generic drugs as a supplement. Patients should choose treatment plans rationally under the guidance of doctors, and pay attention to the latest developments in relevant medical insurance policies to strive for better treatment support and financial help.

Reference materials:https://www.drugs.com/